An anonymous director reports

PROMIS NEUROSCIENCES HOLDS ANNUAL MEETING OF SHAREHOLDERS ALL RESOLUTIONS APPROVED

Promis Neurosciences Inc.'s annual meeting of shareholders was held by virtual webcast meeting on Thursday, June 29, 2023, at 9:30 a.m. Eastern Time. With 51.23 per cent of common shares represented at the meeting, and 93.51 per cent Series 1 preferred shares represented at the meeting, shareholders approved all resolutions by a highly favourable majority. In compliance with securities regulations and Toronto Stock Exchange (TSX) requirements, the corporation has posted the results of the voting below.

All resolutions passed

At the meeting, holders of common shares were asked to consider and vote on the following:

1. Election of directors

Common shareholders re-elected seven directors of the corporation. Dr. Gail Farfel, chief executive officer of Promis since September, 2022, was also elected as a director.

2. Appointment of auditor

Common shareholders voted in favour of the ordinary resolution to appoint Baker Tilly U.S. LLP as auditor of the corporation for the ensuing year and to authorize the directors to fix the auditor's remuneration.

At the meeting, common shareholders and the holders of Series 1 preferred shares were asked to consider the following:

3. Continuance resolution

Common shareholders and Series 1 preferred shareholders, voting together, voted in favour of a special resolution authorizing the company to continue into Ontario under the Business Corporations Act (Ontario) (the OBCA).

About Promis Neurosciences Inc.

Promis Neurosciences is a development-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. The company's proprietary target discovery engine applies a thermodynamic, computational discovery platform -- Promis and Collective Coordinates -- to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, the company is developing novel antibody therapeutics for AD, ALS and MSA. Promis has offices in Toronto, Ont., and Cambridge, Mass. Promis is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

We seek Safe Harbor.